CD4 and myeloid sarcoma: Furthermore, TIGIT is expressed at normal levels in patients with MS and the inhibitory effects of TIGIT signaling pathway on CD4+ T cells from MS patients are functional, suggesting the potential use of this agonistic Ab in clinical for MS (148).